Lapatinib: all 212 studies that test it
Page 2 of 3. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast CancerStatus unknownNCT03273595Phase 2
- Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal CancerStatus unknownNCT03225937Phase 2
- A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs HerceptinStatus unknownNCT03085368Phase 2/3
- Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal DiseaseCompletedNCT02581124Phase 1
- Overcoming Endocrine Resistance in Metastatic Breast CancerStatus unknownNCT02394496Phase 3
- Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced CancerCompletedNCT02342587Phase 2
- Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 TherapiesStatus unknownNCT02238509Phase 2
- Lapatinib Plus Trametinib in KRAS Mutant NSCLCCompletedNCT02230553Phase 1/2
- A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast CancerTerminatedNCT02131506Phase 1
- Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade GliomaCompletedNCT02101905Phase 1
- T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast CancerCompletedNCT02073916Phase 1
- Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver MetastasisCompletedNCT02015169Phase 2
- Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by SurgeryActive, not recruitingNCT01947023Phase 1
- Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + LapatinibCompletedNCT01875666Early Phase 1
- Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS MetastasisCompletedNCT01783756Phase 1/2
- Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/TrastuzumabStatus unknownNCT01730677Phase 2
- Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By SurgeryTerminatedNCT01705340Phase 1
- Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial CancerWithdrawnNCT01700010Phase 2
- Single-center Investigator Initiated Pilot Study Investigating the Tumor Response of Squamous Cell Carcinoma Lesions in Patients Under Lapatinib TreatmentTerminatedNCT01666431Phase 2
- ErbB2 Positive Metastatic Breast CancerTerminatedNCT01658358Phase 1/2
- Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.CompletedNCT01636908Not applicable
- Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast CancerTerminatedNCT01589861Phase 1/2
- A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast CancerCompletedNCT01526369Phase 3
- Lapatinib and Bortezomib in Patients With Advanced MalignanciesTerminatedNCT01497626Phase 1
- The Myocet/Lapatinib Study. ICORG 10-03, V5TerminatedNCT01495884Phase 1/2
- A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.CompletedNCT01485926Phase 2
- Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast CancerTerminatedNCT01477060Phase 2
- Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid TumorsCompletedNCT01454804Phase 1
- A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or CarcinosarcomaStatus unknownNCT01454479Phase 1
- Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab OnlyCompletedNCT01434303Phase 1
- Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic DiseaseTerminatedNCT01427322Early Phase 1
- Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast CancerStatus unknownNCT01309607Phase 2
- A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive CancerCompletedNCT01304784Phase 1
- Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast CancerCompletedNCT01300962Phase 1
- Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast CancerCompletedNCT01290354Phase 1
- Lapatinib and RAD-001 for HER2 Positive Metastatic Breast CancerStatus unknownNCT01283789Phase 2
- Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast CancerTerminatedNCT01281163Phase 1
- Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast CancerCompletedNCT01275859Phase 2
- Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer.CompletedNCT01262469Phase 2
- A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before CystectomyTerminatedNCT01245660Early Phase 1
- Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast CancerCompletedNCT01245205Phase 1
- Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast CancerTerminatedNCT01238029Phase 1
- Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast TumorsCompletedNCT01218529Phase 2
- Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast CancerWithdrawnNCT01205217Phase 2
- Lapatinib and Cetuximab in Patients With Solid TumorsCompletedNCT01184482Phase 1
- Primary Chemotherapy in Patients With HER2-positive Early Breast CancerCompletedNCT01172223Phase 1/2
- A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer PatientsTerminatedNCT01161368Phase 2
- Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal CancerTerminatedNCT01145404Phase 2
- Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast CancerCompletedNCT01138384Phase 1/2
- A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast CancerWithdrawnNCT01137994Phase 2
- Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT)CompletedNCT01133912Phase 1
- Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction CancerTerminatedNCT01123473Phase 2
- Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast CancerActive, not recruitingNCT01104571Phase 3
- Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast CancerCompletedNCT01068704Phase 2
- Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast CancerCompletedNCT01044485Phase 1/2
- ELBA: Exemestane and Lapatinib in Advanced Breast CancerWithdrawnNCT01005641Phase 2
- A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of LapatinibCompletedNCT00996762Phase 1
- The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid TumorsCompletedNCT00984425Phase 1
- Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain MetastasesCompletedNCT00967031Phase 2
- Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic CancerCompletedNCT00962312Phase 2
- A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the UrotheliumStatus unknownNCT00949455Phase 2/3
- Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast CancerCompletedNCT00912275Phase 1/2
- Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal CancerTerminatedNCT00888810Phase 2
- A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast CancerCompletedNCT00849329Phase 1
- A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer PatientsCompletedNCT00821054Phase 1
- Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor CellsTerminatedNCT00820924Phase 2
- Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast CancerTerminatedNCT00754702Phase 2
- Lapatinib and Circulating Tumor Cells in Breast CancerCompletedNCT00694252Phase 2
- Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor TherapyStatus unknownNCT00688194Phase 3
- Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By SurgeryCompletedNCT00662636Phase 1
- APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)TerminatedNCT00657137Phase 2
- Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast CancerCompletedNCT00650910Phase 1
- Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast CancerCompletedNCT00614978Phase 1
- Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2CompletedNCT00544804Phase 1
- Bevacizumab in Multiple Phase I CombinationsCompletedNCT00543504Phase 1
- A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding PhaseCompletedNCT00528281Phase 1
- Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid TumorsCompletedNCT00516672Phase 1
- A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of LapatinibWithdrawnNCT00513253Phase 1
- Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast CancerCompletedNCT00513058Phase 1
- A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast CancerStatus unknownNCT00486668Phase 3
- GW572016 In Patients With Advanced Or Metastatic Breast CancerCompletedNCT00462956Phase 1
- INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer PatientsWithdrawnNCT00455039Phase 1/2
- Phase I/II Study of Neoadjuvant Lapatinib in Breast CancerCompletedNCT00450892Phase 1/2
- Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric CancerStatus unknownNCT00450203Phase 2/3
- Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)CompletedNCT00388076Phase 1
- Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast CancerCompletedNCT00379509Phase 1
- GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast CancerCompletedNCT00371488Phase 1
- Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast CancerCompletedNCT00359190Phase 1
- Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted TherapyWithdrawnNCT00343759Phase 2
- Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian CancerTerminatedNCT00317434Phase 1
- Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast CancerCompletedNCT00316875Phase 1
- Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer PatientsCompletedNCT00316407Phase 1/2
- Lapatinib and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT00313599Phase 1
- Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast CancerCompletedNCT00299286Phase 2
- Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The EsophagusCompletedNCT00259987Phase 2
- To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer PatientsCompletedNCT00258050Phase 1
- GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast CancerTerminatedNCT00251433Phase 1
- Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma EsophagusTerminatedNCT00239200Phase 2
- Rollover Study Of Lapatinib In Cancer PatientsCompletedNCT00169533Phase 1
- Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer PatientsCompletedNCT00158782Phase 1